Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

There Will Be Healthy Competition Between India And China - Two Emerging Biotech Superpowers - Says Reinhard Gluck, Research Head At Zydus Cadila And Chairman, Swiss Biotech Association

This article was originally published in PharmAsia News

Executive Summary

Reinhard Gluck, chairman of the Swiss Biotech Association, had lucrative offers pouring in after Crucell sold Italy-based Etna Biotech, the research arm for which he worked, to India's Zydus Cadila in 2008. Gluck, known for his ability in developing vaccines, preferred to stay on with his new employer, impressed by the opportunities that could emerge from the Indian connection. Excited by Cadila's commitment to the long haul, Gluck says it would not have been as good a call to work for any other established bigger multinational company. On the sidelines of the recent BioPharma Asia conference in Singapore, Gluck sat down with PharmAsia News' India bureau cheif to speak on issues ranging from funding of biotech initiatives to future vaccines and the research outlook in Asia.
Advertisement

Related Content

Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Billion In Sales By 2015
Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Billion In Sales By 2015
Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Bil In Sales By 2015
Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Bil In Sales By 2015
Advertisement
UsernamePublicRestriction

Register

SC074539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel